Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
June 02 2023 - 7:00AM
Business Wire
Event to be webcast live on Wednesday, June 7,
2023 at 4:30 p.m. ET
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced it will host a conference call and live webcast to
present initial monotherapy data from its Phase 1 MYTHIC clinical
trial evaluating RP-6306, as well as to provide early insights on
ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m.
Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein
Kinase Membrane-associated tyrosine- and threonine- specific cdc-2
inhibitory kinase) synthetic lethal inhibitor in clinical
development for the treatment of molecularly selected advanced
solid tumors.
Conference Call and Webcast Details:
To access the call, please dial (877) 870-4263 (U.S. and Canada)
or (412) 317-0790 (international) at least 10 minutes prior to the
start time and ask to be joined to the Repare Therapeutics call. A
live video webcast will be available in the Investor section of the
Company’s website at
https://ir.reparerx.com/news-and-events/events. A webcast replay
will also be archived for at least 30 days.
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based
screening approach that utilizes proprietary isogenic cell lines to
identify novel and known synthetic lethal gene pairs and the
corresponding patients who are most likely to benefit from the
Company’s therapies based on the genetic profile of their tumors.
Repare’s platform enables the development of precision therapeutics
in patients whose tumors contain one or more genomic alterations
identified by SNIPRx® screening, in order to selectively target
those tumors in patients most likely to achieve clinical benefit
from resulting product candidates.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes RP-6306, a PKMYT1
inhibitor currently in Phase 1 clinical development; camonsertib
(also known as RP-3500 or RG6526), a potential leading ATR
inhibitor currently in Phase 1/2 clinical development and partnered
with Roche; a preclinical Polθ inhibitor program; as well as
several additional, undisclosed preclinical programs, including
RP-1664. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230602005075/en/
Repare Contact: Robin Garner Executive Director and Head
of Investor Relations Repare Therapeutics Inc.
investor@reparerx.com Investors: Matthew DeYoung Argot
Partners repare@argotpartners.com Media: David Rosen Argot
Partners david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Apr 2024 to May 2024
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From May 2023 to May 2024